老年1型发作性睡病患者脑淀粉样蛋白负荷降低
本研究比较了23例65岁及以上1型发作性睡病(NT1)患者与来自ADNI队列(n=69)和MAPT-18F AV45-PET队列(n=23)的年龄性别匹配无痴呆对照者的认知及18F-florbetapir PET数据。NT1患者皮层淀粉样蛋白负荷低于两个对照组,仅4.4%的NT1患者PET淀粉样蛋白阳性,而ADNI组为27.5%、MAPT-AV45组为30.4%。NT1组淀粉样蛋白负荷与脑脊液食欲素A、阿尔茨海默病脑脊液标志物或神经心理特征无关。
要点
- 老年NT1患者皮层/小脑SUV比值低于ADNI和MAPT-AV45对照组。
- 仅1例NT1患者(4.4%)PET淀粉样蛋白阳性,低于两对照组。
- NT1组淀粉样蛋白负荷与脑脊液食欲素A、AD标志物及认知无关。
核心结论
- 18F-florbetapir PET评估的NT1患者脑淀粉样蛋白负荷较低,提示淀粉样斑块出现延迟。
研究设计与样本
- 比较23例65岁及以上NT1患者与年龄性别匹配的无临床痴呆对照者(ADNI队列n=69,MAPT-18F AV45-PET队列n=23)的认知和18F-florbetapir PET数据。
主要发现
- NT1组平均皮层/小脑SUV比值为0.95±0.15,ADNI组为1.11±0.18(p<0.0001),MAPT-AV45组为1.14±0.17(p=0.0005)。
- 使用所有皮层下参考区及所有皮层感兴趣区(除扣带回外)均得到相似结果。
- NT1组仅1例(4.4%)PET淀粉样蛋白阳性,ADNI组为27.5%,MAPT-AV45组为30.4%。
- NT1组皮层或区域淀粉样蛋白负荷与脑脊液食欲素A、脑脊液AD生物标志物或神经心理特征无关。
关键数值与推荐
- 皮层/小脑SUV比值≥1.17定义为PET淀粉样蛋白阳性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether brain amyloid burden in elderly patients with narcolepsy type 1 (NT1) is lower than in controls, and to assess in patients with NT1 the relationships between amyloid burden, cerebral spinal fluid (CSF) markers of Alzheimer disease (AD), CSF orexin-A, and cognitive profile. METHODS: Cognitive and 18 F-florbetapir positron emission tomography (PET) data were compared in patients with NT1 aged ≥ 65 years (n = 23) and in age- and sex-matched controls free of clinical dementia selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 69) and the Multi-Domain Intervention Alzheimer's Prevention Trial (MAPT-18F AV45-PET; n = 23) cohorts. The standardized uptake values (SUVs) of the cortical retention index for 6 regions of interest were computed and averaged to create a mean SUV ratio normalized to 3 subcortical reference regions (cerebellum, pons, and a composite region). A cortical/cerebellum SUV ratio ≥ 1.17 defined positive PET amyloid. RESULTS: Lower cortical amyloid burden was observed in the NT1 than in the ADNI and MAPT-AV45 groups (mean cortical/cerebellum SUV ratios = 0.95 ± 0.15, 1.11 ± 0.18 [p < 0.0001], and 1.14 ± 0.17 [p = 0.0005], respectively). Similar results were obtained with all subcortical reference regions and for all cortical regions of interest, except cingulum. Only 1 patient with NT1 (4.4%) had positive PET amyloid compared with 27.5% in the ADNI and 30.4% in the MAPT-AV45 group. In the NT1 group, cortical or regional amyloid load was not associated with CSF orexin-A, CSF AD biomarkers, or neuropsychological profile. INTERPRETATION: Lower brain amyloid burden, assessed by 18 F-florbetapir PET, in patients with NT1 suggests delayed appearance of amyloid plaques. ANN NEUROL 2019;85:74-83.
引用
- Gabelle A, Jaussent I, Bouallègue FB, et al. Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Ann Neurol. 2018. PMID: 30387527. doi:10.1002/ana.25373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。